Literature DB >> 31966992

CO-EXISTENCE OF PRIMARY HYPERPARATHYROIDISM DUE TO MULTIPLE ENDOCRINE NEOPLASIA 1 IN A HYPERCALCEMIC PATIENT WITH GRAVES DISEASE.

Shalini Bhat, Susan Davis.   

Abstract

OBJECTIVE: Hypercalcemia in a patient with Graves disease can occur in up to 22% of cases. The mechanism is thought to be increased bone resorption. There are more rare causes of hypercalcemia in these patients with hyperthyroidism, such as hyperparathyroidism, which occurs in less than 1% of patients. We describe a rare occurrence of primary hyperparathyroidism due to multiple endocrine neoplasia type 1 (MEN 1) in a Graves disease patient presenting with hyperthyroidism and hypercalcemia.
METHODS: The patient initially presented with a 3-week history of nausea, vomiting, and abdominal pain. She also had an 8-week history of a 12-pound weight loss. She was diagnosed with hyperthyroidism secondary to Graves disease and was noted to have concurrent hypercalcemia. She was diagnosed with primary hyperparathyroidism. The patient underwent subtotal thyroidectomy and total parathyroidectomy with forearm autotransplantation. Subsequent genetic testing confirmed the diagnosis of MEN 1.
RESULTS: A review of the literature was conducted to identify previous studies pertaining to concurrent hypercalcemia in hyperthyroid patients, focusing on reports related to their diagnosis and management.
CONCLUSION: Co-existing primary hyperparathyroidism due to MEN 1, although rare, should be considered in a patient with hyperthyroidism and hypercalcemia. A thorough evaluation is necessary to avoid a delay in the correct diagnosis and treatment of the underlying conditions. Clinicians should be aware of the rare occurrence of primary hyperparathyroidism due to MEN 1 in a Graves disease patient presenting with hyperthyroidism and hypercalcemia.
Copyright © 2019 AACE.

Entities:  

Year:  2019        PMID: 31966992      PMCID: PMC6876967          DOI: 10.4158/ACCR-2018-0217

Source DB:  PubMed          Journal:  AACE Clin Case Rep        ISSN: 2376-0605


  4 in total

1.  Hypercalcemia of thyrotoxicosis.

Authors:  J D Baxter; P K Bondy
Journal:  Ann Intern Med       Date:  1966-09       Impact factor: 25.391

2.  Severe hypocalcemia complicated by postsurgical hypoparathyroidism and hungry bone syndrome in a patient with primary hyperparathyroidism, Graves' disease, and acromegaly.

Authors:  Seigo Tachibana; Shinya Sato; Tadao Yokoi; Ryoko Nagaishi; Yuko Akehi; Toshihiko Yanase; Hiroyuki Yamashita
Journal:  Intern Med       Date:  2012-07-15       Impact factor: 1.271

3.  Bone remodelling markers and serum cytokines in patients with hyperthyroidism.

Authors:  Aysen Akalin; Omer Colak; Ozkan Alatas; Belgin Efe
Journal:  Clin Endocrinol (Oxf)       Date:  2002-07       Impact factor: 3.478

Review 4.  Coexisting hyperparathyroidism with thyrotoxicosis.

Authors:  D M McGowan; A Vaswani; I Shperling
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

  4 in total
  2 in total

1.  Coexistence of Graves' disease and primary hyperparathyroidism: a case description.

Authors:  Fang Zhang; Xiaohui Pan; Nanwei Tong; Qingguo Lü
Journal:  Quant Imaging Med Surg       Date:  2022-05

2.  Multiple endocrine neoplasia type 1 with refractory hypoglycemia and lung and liver metastases: a case report.

Authors:  Yong Wang; Hui Zhang
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.